SMMT as reported
Summit Therapeutics Inc. reported $0 of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.
$0
Revenue, trailing twelve months · to Q4 2023 · every figure below is as filed, with no scoring applied
- Net Income
- −$856M
Net Income · +15% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$460M
Free Cash Flow · +122% year on year · trailing twelve months to Q2 2026
- EPS
- −$1.11
EPS · +8.8% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $0 | n/a | Q4 2023 · 10 quarters behind |
| Net Income | −$856M | +15% | Q2 2026 |
| EPS | −$1.11 | +8.8% | Q2 2026 |
| Op Margin | −8085% | n/a | Q3 2022 · 15 quarters behind |
| Net Margin | −9053% | n/a | Q3 2022 · 15 quarters behind |
| ROE | −250% | n/a | Q2 2026 |
| ROA | −199% | n/a | Q2 2026 |
| Free Cash Flow | −$460M | +122% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Summit Therapeutics Inc. (SMMT) - Revenue & ProfitRevenue & ProfitSummit Therapeutics Inc. (SMMT)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com